Preeclampsia (PE) is the most important, serious medical disorder of human pregnancy. Clinical management involves alleviation of hypertension, prevention of seizures and careful timing of delivery. The aetiology of PE is complex and cures have not been forthcoming. We plan to develop novel stem cell-based therapies to improve the common, clinical features of PE, consequently reducing the risk of prematurity. Our preliminary data show that placental MSCs can reduce endothelial dysfunctions and therefore we will test whether placental MSCs can reduce endothelial dysfunction in animal model of PE and cure PE.